Genedrive (D6M) AI Stock Analysis

Genedrive

(Frankfurt:D6M)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Recurring consumables revenueGenedrive’s business model centers on instrument placements plus recurring single-use test cartridges. That installed-base + consumables model creates predictable, high-frequency revenue streams as utilization scales, supporting long-term margin improvement and cash conversion if adoption continues.

Negative Factors

Persistent cash burnOperating and free cash flow remain deeply negative, implying ongoing reliance on external financing. Persistent cash burn constrains strategic options, risks recurrent dilution or covenant pressure, and reduces the effective runway unless revenue scale or gross margins improve materially.

Genedrive (D6M) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 15.65M
Dividend Yield: ―
Average Volume (3M): 5,200
Price to Earnings (P/E): -0.9
Beta (1Y): 5.69
Revenue Growth: 63.61%
EPS Growth: 74.73%
Country: Germany
Employees: 43
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Diagnostics & Research

Genedrive Business Overview & Revenue Model

Company Description

Genedrive Plc, a molecular diagnostics firm established in Manchester, UK, in 2000 (and known as Epistem Holdings Plc until its name change in July 2016), focuses on developing and commercializing innovative point-of-care diagnostic platforms. These...

Genedrive Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:D6M against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GB:EKF	64Neutral	GBP 102.71M	41.38	3.58%	―	2.26%	-57.04%
GB:ONT	59Neutral	GBP 2.18B	-17.72	-27.36%	―	14.80%	16.88%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GB:ABDX	46Neutral	GBP 22.75M	-16.36	-34.31%	―	30.42%	43.16%
GB:RENX	44Neutral	GBP 36.54M	-3.44	675.00%	―	―	―
GB:APTA	43Neutral	GBP 10.23M	-9.83	-46.61%	―	28.35%	57.14%

* Healthcare Sector Average

Performance Comparison

DE:D6M and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:D6M	Genedrive plc	0.01	-0.01	-54.55%
GB:EKF	EKF Diagnostics Holdings	24.00	-2.00	-7.69%
GB:RENX	Renalytix Plc OTC	5.45	-1.80	-24.83%
GB:ABDX	Abingdon Health PLC	9.00	2.75	44.00%
GB:APTA	Aptamer Group Plc	0.29	-0.52	-64.02%
GB:ONT	Oxford Nanopore Technologies PLC	222.60	86.30	63.32%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Genedrive AI Stock Analysis